CATX Perspective Therapeutics, Inc.
Executive Summary
A significant institutional cluster formed in CATX during Q3 2024, with 8 buyers accumulating $13.3M in net new positions (total holdings $20.2M) while 3 sellers reduced holdings by $10.5M. The buying is dominated by active asset managers including Adage Capital Partners ($6.2M add) and multiple doublings by Schwab, AllianceBernstein, and Victory Capital, suggesting a shared bullish thesis on Perspective Therapeutics' radiopharmaceutical pipeline. However, the cluster is partially offset by near-complete exits from Citadel and Walleye Capital, and the stock's poor historical performance following prior reports (0% win rate at T+20) warrants caution.
Key Financial Metrics
Institutional Positions
Net institutional flow: $2.8M
▲ Buyers (8)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Adage Capital Partners Gp | ADD | +96.5% | $10.0M | $6.2M |
| Schwab | DOUBLED | +221.7% | $5.8M | $4.4M |
| Victory Capital Management | DOUBLED | +328.7% | $674.0K | $556.0K |
| Rhumbline Advisers | ADD | +43.9% | $1.2M | $584.0K |
| Alliancebernstein | DOUBLED | +104.3% | $663.0K | $421.0K |
▼ Sellers (3)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Citadel | NEAR_EXIT | -97.9% | $5.7M | -$5.6M |
| Walleye Capital | NEAR_EXIT | -96.5% | $5.1M | -$4.9M |
| Strs Ohio | TRIM | -39.1% | $87.0K | -$16.0K |
Actionable Insight
The strong active-manager buying cluster suggests a shared thesis around CATX's radiopharmaceutical pipeline, but the near-complete exits by Citadel and Walleye create a mixed signal. Given the stock's poor historical follow-through (0% T+20 win rate), traders should wait for a concrete catalyst (e.g., clinical data, partnership, or regulatory update) before acting on this cluster alone. Monitor upcoming Q4 2024 13F filings to see if the buying persisted or reversed.
Key Facts
- 8 institutional buyers accumulated $13.3M in net new CATX positions during Q3 2024
- Adage Capital Partners added $6.2M, the largest single buy, increasing its position by 96.5%
- Schwab doubled its stake (+221.7%), now holding $5.8M
- Victory Capital Management tripled its position (+328.7%)
- Citadel and Walleye Capital each exited ~97% of their positions, selling a combined $10.4M
- Active asset managers dominate the buying side (7 of 8 buyers), not passive rebalancing
- Historical reports on CATX show a 0% win rate at T+20 across 6 settled reports, with average T+20 return of -10.82%
Financial Impact
8 institutional buyers added $13.3M in net new CATX positions while 3 sellers reduced holdings by $10.5M, for a net institutional inflow of approximately $2.8M
Risk Factors
- 13F data is 45+ days stale; positions may have been unwound since quarter-end
- Historical CATX reports show consistent negative returns at T+20 following any signal
- Large sellers (Citadel, Walleye) may have material non-public information or a bearish thesis
- Pre-revenue biotech with binary pipeline risk — institutional buying does not guarantee clinical success
Market Snapshot
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-CATX-2024-Q3 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
3d ago
|
Institutional Cluster
| $2.96 awaiting T+1 | awaiting T+1 | — | — |
|
Jun 11, 2026
3d ago
|
Institutional Cluster
| $2.96 awaiting T+1 | awaiting T+1 | — | — |
|
Jun 3, 2026
11d ago
|
Press Release
| $3.56 $3.25 | ▼ −8.71% | ▼ −9.11% | — |
|
Jun 1, 2026
13d ago
|
8-K
| $3.66 $3.60 | ▼ −1.64% | ▼ −1.78% | — |
|
May 21, 2026
24d ago
|
Press Release
| $3.98 $4.16 | ▲ +4.52% | ▲ +3.94% | — |
|
May 18, 2026
27d ago
|
Press Release
| $3.76 $3.63 | ▼ −3.46% | ▼ −2.81% | — |
|
May 11, 2026
4w ago
|
8-K
| $3.77 $3.77 | · 0.00% | ▼ −0.54% | — |
|
May 4, 2026
5w ago
|
8-K
| $3.65 $3.82 | ▲ +4.66% | ▲ +3.27% | — |
|
Apr 24, 2026
7w ago
|
Press Release
| $4.51 $4.27 | ▼ −5.32% | ▼ −5.49% | — |
|
Apr 20, 2026
7w ago
|
Press Release
| $4.55 $4.64 | ▲ +1.98% | ▲ +2.63% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access